SCHEMBL2808617

SCHEMBL2808617

NC(=O)CCCCC(=O)NO

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 9/20 0.74
HDAC8 Q9BY41 9/20 0.74
HDAC6 Q9UBN7 5/20 0.74
HDAC3 O15379 4/20 0.74
HDAC2 Q92769 4/20 0.74
HDAC5 Q9UQL6 3/20 0.74
HSP90AA1 P07900 1/20 0.58
ENPEP Q07075 1/20 0.48
KDM4E B2RXH2 2/20 0.48
KDM6B O15054 1/20 0.48
KDM5C P41229 1/20 0.48
FOLH1 Q04609 1/20 0.48
EGLN1 Q9GZT9 1/20 0.48
PHF8 Q9UPP1 1/20 0.48
KDM2A Q9Y2K7 1/20 0.48
HDAC11 Q96DB2 3/20 0.47
HDAC10 Q969S8 2/20 0.47
NCOR2 Q9Y618 2/20 0.47
HDAC4 P56524 2/20 0.45
HDAC7 Q8WUI4 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2810504 0.97 HDAC1 (0.79) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL29055202 0.97 HDAC1 (0.79) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL2813818 0.97 HDAC1 (0.79) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL976350 0.94 HDAC1 (0.65) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL11768749 0.88 HDAC1 (0.93) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL27643837 0.86 FOLH1 (0.57) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL137189 0.86
Azelaic Bis Hydroxamic Acid SCHEMBL4741072 0.85 HDAC1 (1.00) HDAC1HDAC8HDAC6HDAC3HDAC2
Suberohydroxamic Acid SCHEMBL2159033 0.85 HDAC1 (1.00) HDAC1HDAC8HDAC6HDAC3HDAC2
SCHEMBL11764904 0.85 HDAC1 (1.00) HDAC1HDAC8HDAC6HDAC3HDAC2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115286583-B Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2024-01-30 CN claimed
CN-115521228-B BChE and HDAC double-target inhibitor and preparation method and application thereof 中国药科大学 2023-08-22 CN claimed
CN-108003111-A Double target spot inhibitor of a kind of HDAC1 and IDO1 and its preparation method and application 华东理工大学 2018-05-08 CN claimed
CN-104592114-B Substd quinolines histone deacetylases inhibitor and preparation method and application 山东大学 2017-07-07 CN claimed
CN-119143625-A Preparation method of alkoxyamine hydrochloride 河南立诺制药有限公司 2024-12-17 CN disclosed
CN-115286583-B Diphenylamino pyrimidine-containing compound, preparation and application thereof as HDACs enzyme inhibitor 山东大学 2024-01-30 CN disclosed
CN-115521228-B BChE and HDAC double-target inhibitor and preparation method and application thereof 中国药科大学 2023-08-22 CN disclosed
CN-113387938-B Substituted pyrimidine compound, preparation method, intermediate and application thereof 上海科技大学 2023-08-18 CN disclosed
CN-107619407-B Bis- target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application 山东大学 2019-05-24 CN disclosed
CN-108003111-A Double target spot inhibitor of a kind of HDAC1 and IDO1 and its preparation method and application 华东理工大学 2018-05-08 CN disclosed
CN-107619407-A Double target spot inhibitor of HDAC and VEGFR based on pazopanib structure and its preparation method and application 山东大学 2018-01-23 CN disclosed
CN-104592114-B Substd quinolines histone deacetylases inhibitor and preparation method and application 山东大学 2017-07-07 CN disclosed
EP-2083005-A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2009-07-29 EP disclosed
EP-1598067-B1 Carbamic acid compounds comprising an amide linkage for the treatment of malaria TOPOTARGET UK LTD (GB) 2009-05-06 EP disclosed
WO-2009026446-A2 HDAC INHIBITORS ARQULE, INC. (US) 2009-02-26 WO disclosed
EP-1335898-B1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS TOPOTARGET UK LTD (GB) 2005-11-23 EP disclosed
EP-1598067-A1 Carbamic acid compounds comprising an amide linkage as HDAC inhibitors TopoTarget UK Limited (GB) 2005-11-23 EP disclosed
US-20040092598-A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors TOPOTARGET UK LIMITED (GB) 2004-05-13 US disclosed
EP-1335898-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS Prolifix Limited (GB) 2003-08-20 EP disclosed
WO-2002026696-A1 CARBAMIC ACID COMPOUNDS COMPRISING AN AMIDE LINKAGE AS HDAC INHIBITORS PROLIFIX LIMITED (GB) 2002-04-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040092598-A1 Carbamic acid compounds comprising an amide linkage as hdac inhibitors HDAC1, HDAC11, HDAC3 HDAC1 1/4885HDAC8 6/4885HDAC6 11/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.